{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:19:51Z","timestamp":1793679591823,"version":"4.5.1"},"reference-count":59,"publisher":"American Association for Cancer Research (AACR)","issue":"7","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003803"],"award-info":[{"award-number":["82003803"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92053118"],"award-info":[{"award-number":["92053118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970671"],"award-info":[{"award-number":["31970671"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100216"],"award-info":[{"award-number":["82100216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGD) and proteolysis-targeting chimeras (PROTAC), overcome traditional occupancy-based inhibitor limitations and facilitate therapeutic development against \u201cundruggable\u201d disease-causing proteins. However, resistance to TPD is common, highlighting the need to further understand the driving mechanisms to improve treatment efficacy. In this study, we identified a critical role of mTOR signaling in regulating PROTAC and MGD efficacy in vitro and in vivo. Activation or inhibition of mTOR diminished or enhanced degradation efficacy of all proteasome-dependent TPD modalities tested, respectively. Mechanistically, mTOR inhibition suppressed de novo protein synthesis, thus creating a synthetic vulnerability by depleting replenishment of proteins targeted by PROTACs or MGDs. When applied to myeloma, mTOR inhibitors restored sensitivity to pomalidomide, one of the best characterized MGDs, in resistant cell lines and reduced malignant plasma cells in relapsed\/refractory patients. This study reveals a clinically translatable strategy combining approved mTOR inhibitors with MGDs or PROTACs to enhance the therapeutic index of TPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>mTOR inhibition enhances targeted protein degradation efficacy and overcomes clinical resistance to molecular glue degraders and proteolysis targeting chimeras.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-3941","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:42:53Z","timestamp":1768329773000},"page":"1690-1706","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protein Degradation Approaches"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-0096","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030bhh786","id-type":"ROR","asserted-by":"publisher"}],"name":"ShanghaiTech University 1 School of Life Science and Technology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-023X","authenticated-orcid":false,"given":"Yifeng","family":"Sun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010826a91","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai Ninth People\u2019s Hospital 2 Department of Hematology, , Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-6795","authenticated-orcid":false,"given":"Tian-Yu","family":"Song","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030bhh786","id-type":"ROR","asserted-by":"publisher"}],"name":"ShanghaiTech University 1 School of Life Science and Technology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7980-6906","authenticated-orcid":false,"given":"Si-Yuan","family":"Ni","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030bhh786","id-type":"ROR","asserted-by":"publisher"}],"name":"ShanghaiTech University 1 School of Life Science and Technology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1251-7285","authenticated-orcid":false,"given":"Yi-Sheng","family":"Pu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030bhh786","id-type":"ROR","asserted-by":"publisher"}],"name":"ShanghaiTech University 1 School of Life Science and Technology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-4841","authenticated-orcid":false,"given":"Yuan-Chen","family":"Chang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05a0ya142","id-type":"ROR","asserted-by":"publisher"}],"name":"Broad Institute of MIT and Harvard 3 , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-4569","authenticated-orcid":false,"given":"Wenrong","family":"Zhou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04eh3ca90","id-type":"ROR","asserted-by":"publisher"}],"name":"WuXi AppTec (Shanghai) Co, Ltd 4 Oncology and Immunology Unit, WuXi Biology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9565-258X","authenticated-orcid":false,"given":"Zhen-Gang","family":"Peng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04eh3ca90","id-type":"ROR","asserted-by":"publisher"}],"name":"WuXi AppTec (Shanghai) Co, Ltd 4 Oncology and Immunology Unit, WuXi Biology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-306X","authenticated-orcid":false,"given":"Jiajia","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010826a91","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai Ninth People\u2019s Hospital 2 Department of Hematology, , Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-5242","authenticated-orcid":false,"given":"Jun","family":"Shi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010826a91","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai Ninth People\u2019s Hospital 2 Department of Hematology, , Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-8626","authenticated-orcid":false,"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010826a91","id-type":"ROR","asserted-by":"publisher"}],"name":"Shanghai Ninth People\u2019s Hospital 2 Department of Hematology, , Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-7008","authenticated-orcid":false,"given":"Yong","family":"Cang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030bhh786","id-type":"ROR","asserted-by":"publisher"}],"name":"ShanghaiTech University 1 School of Life Science and Technology, , Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026040203103328500_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41580-021-00448-5","article-title":"Ubiquitin ligases: guardians of mammalian development","volume":"23","author":"Cruz Walma","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026040203103328500_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tibs.2024.12.006","article-title":"Routes to molecular glue degrader discovery","volume":"50","author":"Liu","year":"2025","journal-title":"Trends Biochem Sci"},{"key":"2026040203103328500_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026040203103328500_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026040203103328500_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2026040203103328500_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2026040203103328500_bib7","doi-asserted-by":"crossref","first-page":"685106","DOI":"10.3389\/fcell.2021.685106","article-title":"Opportunities and challenges of small molecule induced targeted protein degradation","volume":"9","author":"He","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026040203103328500_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026040203103328500_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","article-title":"The clinical significance of cereblon expression in multiple myeloma","volume":"38","author":"Schuster","year":"2014","journal-title":"Leuk Res"},{"key":"2026040203103328500_bib10","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"2026040203103328500_bib11","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"2026040203103328500_bib12","first-page":"2215","article-title":"Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chem Biol"},{"key":"2026040203103328500_bib13","doi-asserted-by":"crossref","first-page":"108532","DOI":"10.1016\/j.celrep.2020.108532","article-title":"Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins","volume":"34","author":"Shirasaki","year":"2021","journal-title":"Cell Rep"},{"key":"2026040203103328500_bib14","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat Commun"},{"key":"2026040203103328500_bib15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s42003-021-02801-y","article-title":"PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates","volume":"4","author":"Shimizu","year":"2021","journal-title":"Commun Biol"},{"key":"2026040203103328500_bib16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"2026040203103328500_bib17","doi-asserted-by":"crossref","first-page":"e5139","DOI":"10.1002\/bmc.5139","article-title":"Pharmacokinetics, bioavailability and metabolism of CC-92480 in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry","volume":"35","author":"You","year":"2021","journal-title":"Biomed Chromatogr"},{"key":"2026040203103328500_bib18","doi-asserted-by":"crossref","first-page":"102811","DOI":"10.1016\/j.sbi.2024.102811","article-title":"Emerging strategies for prospective discovery of molecular glue degraders","volume":"86","author":"Wang","year":"2024","journal-title":"Curr Opin Struct Biol"},{"key":"2026040203103328500_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","article-title":"Molecular glues: the adhesive connecting targeted protein degradation to the clinic","volume":"62","author":"Sasso","year":"2023","journal-title":"Biochemistry"},{"key":"2026040203103328500_bib20","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers13112712","article-title":"Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review","volume":"13","author":"Nishida","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026040203103328500_bib21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/jpm11050334","article-title":"Targeted therapies for multiple myeloma","volume":"11","author":"Leow","year":"2021","journal-title":"J Pers Med"},{"key":"2026040203103328500_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"key":"2026040203103328500_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"2026040203103328500_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/nan.12463","article-title":"Review: mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy","volume":"44","author":"Marsan","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2026040203103328500_bib25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.trecan.2016.10.006","article-title":"mTOR signaling confers resistance to targeted cancer drugs","volume":"2","author":"Guri","year":"2016","journal-title":"Trends Cancer"},{"key":"2026040203103328500_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"2026040203103328500_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","article-title":"Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment","volume":"11","author":"Jiang","year":"2008","journal-title":"Drug Resist Updat"},{"key":"2026040203103328500_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","article-title":"A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"key":"2026040203103328500_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","article-title":"Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute","volume":"14","author":"Wang","year":"2019","journal-title":"Nat Protoc"},{"key":"2026040203103328500_bib30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood"},{"key":"2026040203103328500_bib31","doi-asserted-by":"crossref","first-page":"e40958","DOI":"10.7554\/eLife.40958","article-title":"UBE2G1 governs the destruction of cereblon neomorphic substrates","volume":"7","author":"Lu","year":"2018","journal-title":"Elife"},{"key":"2026040203103328500_bib32","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1158\/0008-5472.CAN-10-3919","article-title":"Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells","volume":"71","author":"Damelin","year":"2011","journal-title":"Cancer Res"},{"key":"2026040203103328500_bib33","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/leu.2012.18","article-title":"5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype","volume":"26","author":"Castro","year":"2012","journal-title":"Leukemia"},{"key":"2026040203103328500_bib34","doi-asserted-by":"crossref","first-page":"9758","DOI":"10.1002\/jcb.28256","article-title":"TIGD1, a gene of unknown function, involves cell-cycle progression and correlates with poor prognosis in human cancer","volume":"120","author":"Yin","year":"2019","journal-title":"J Cell Biochem"},{"key":"2026040203103328500_bib35","doi-asserted-by":"crossref","first-page":"11421","DOI":"10.1038\/s41598-018-29802-y","article-title":"Interplay between human nucleolar GNL1 and RPS20 is critical to modulate cell proliferation","volume":"8","author":"Krishnan","year":"2018","journal-title":"Sci Rep"},{"key":"2026040203103328500_bib36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.2019004147","article-title":"YWHAE\/14-3-3\u03b5 expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma","volume":"136","author":"Xu","year":"2020","journal-title":"Blood"},{"key":"2026040203103328500_bib37","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/epi.16370","article-title":"GATORopathies: the role of amino acid regulatory gene mutations in epilepsy and cortical malformations","volume":"60","author":"Iffland","year":"2019","journal-title":"Epilepsia"},{"key":"2026040203103328500_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ng.2599","article-title":"Mutations in DEPDC5 cause familial focal epilepsy with variable foci","volume":"45","author":"Dibbens","year":"2013","journal-title":"Nat Genet"},{"key":"2026040203103328500_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026040203103328500_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat Med"},{"key":"2026040203103328500_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/or.2022.8459","article-title":"Biochemical and clinical effects of RPS20 expression in renal clear cell carcinoma","volume":"49","author":"Shen","year":"2023","journal-title":"Oncol Rep"},{"key":"2026040203103328500_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026040203103328500_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"2026040203103328500_bib44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"2026040203103328500_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2026040203103328500_bib46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41419-024-06967-1","article-title":"Potential of GSPT1 as a novel target for glioblastoma therapy","volume":"15","author":"Sasayama","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026040203103328500_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"Suppl 7","key":"2026040203103328500_bib48","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1158\/1538-7445.AM2023-3449","article-title":"Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction","volume":"83","author":"Gavory","year":"2023","journal-title":"Cancer Res"},{"key":"2026040203103328500_bib49","doi-asserted-by":"crossref","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"2026040203103328500_bib50","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026040203103328500_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chembiol.2019.10.013","article-title":"Development and characterization of a Wee1 kinase degrader","volume":"27","author":"Li","year":"2020","journal-title":"Cell Chem Biol"},{"key":"2026040203103328500_bib52","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.chembiol.2022.10.007","article-title":"Addressing the enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation","volume":"29","author":"Zhu","year":"2022","journal-title":"Cell Chem Biol"},{"key":"2026040203103328500_bib53","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1073\/pnas.0601637103","article-title":"Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT)","volume":"103","author":"Dieterich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026040203103328500_bib54","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/hmg\/3.suppl_1.1477","article-title":"The molecular genetics of tuberous sclerosis","volume":"3 Spec No","author":"Sampson","year":"1994","journal-title":"Hum Mol Genet"},{"key":"2026040203103328500_bib55","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ajmg.a.31351","article-title":"Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations","volume":"140","author":"Merritt","year":"2006","journal-title":"Am J Med Genet A"},{"key":"2026040203103328500_bib56","doi-asserted-by":"crossref","first-page":"11413","DOI":"10.1073\/pnas.91.24.11413","article-title":"Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene","volume":"91","author":"Yeung","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026040203103328500_bib57","doi-asserted-by":"crossref","first-page":"10573","DOI":"10.1158\/0008-5472.CAN-07-1356","article-title":"TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis","volume":"67","author":"Pacheco-Rodriguez","year":"2007","journal-title":"Cancer Res"},{"key":"2026040203103328500_bib58","first-page":"1408","article-title":"Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer","volume":"59","author":"Couch","year":"1999","journal-title":"Cancer Res"},{"key":"2026040203103328500_bib59","doi-asserted-by":"crossref","first-page":"26089","DOI":"10.1074\/jbc.M504045200","article-title":"Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase","volume":"280","author":"Holz","year":"2005","journal-title":"J Biol Chem"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-3941\/3726080\/can-25-3941.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/7\/1690\/3753564\/can-25-3941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/7\/1690\/3753564\/can-25-3941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:10:49Z","timestamp":1775113849000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/7\/1690\/775634\/Inhibition-of-mTOR-Enhances-the-Efficacy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-3941","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.31923283","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923295","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923274","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923286","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923280","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923292","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923313","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923316","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923304","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923277","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923289","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923301","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923307","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31923319","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8398354","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}